Published in J Clin Microbiol on August 12, 2009
Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections. J Clin Microbiol (2013) 1.25
Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother (2013) 1.22
Fungal endophthalmitis associated with compounded products. Emerg Infect Dis (2014) 1.04
Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother (2011) 1.00
Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy. J Clin Microbiol (2012) 0.99
Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev (2014) 0.99
Molecular epidemiology of Aspergillus fumigatus: an in-depth genotypic analysis of isolates involved in an outbreak of invasive aspergillosis. J Clin Microbiol (2011) 0.99
Keratitis due to Aspergillus flavus: clinical profile, molecular identification of fungal strains and detection of aflatoxin production. Mol Vis (2010) 0.98
Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J Clin Microbiol (2009) 0.98
New taxa in Aspergillus section Usti. Stud Mycol (2011) 0.97
Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother (2011) 0.96
The function and evolution of the Aspergillus genome. Trends Microbiol (2012) 0.94
Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi. J Clin Microbiol (2011) 0.93
High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites. PLoS One (2011) 0.91
Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis. J Clin Microbiol (2011) 0.91
Discrimination of Aspergillus lentulus from Aspergillus fumigatus by Raman spectroscopy and MALDI-TOF MS. Eur J Clin Microbiol Infect Dis (2013) 0.88
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother (2011) 0.86
Epidemiological and Genomic Landscape of Azole Resistance Mechanisms in Aspergillus Fungi. Front Microbiol (2016) 0.84
Involvement of the opportunistic pathogen Aspergillus tubingensis in osteomyelitis of the maxillary bone: a case report. BMC Infect Dis (2013) 0.84
Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000-2009. Eur J Clin Microbiol Infect Dis (2011) 0.83
Discovery of a sexual cycle in Aspergillus lentulus, a close relative of A. fumigatus. Eukaryot Cell (2013) 0.83
Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol (2014) 0.83
Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species. Microb Biotechnol (2016) 0.82
Rapid detection and identification of Aspergillus from lower respiratory tract specimens by use of a combined probe-high-resolution melting analysis. J Clin Microbiol (2012) 0.81
Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis (2015) 0.81
Aspergillus fumigatus-Related Species in Clinical Practice. Front Microbiol (2016) 0.81
Monoclonal antibodies to hyphal exoantigens derived from the opportunistic pathogen Aspergillus terreus. Clin Vaccine Immunol (2011) 0.80
Identification by Molecular Methods and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, India. J Clin Microbiol (2016) 0.80
A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis (2014) 0.80
Identification and susceptibility of Aspergillus section nigri in china: prevalence of species and paradoxical growth in response to echinocandins. J Clin Microbiol (2014) 0.79
Simple and highly discriminatory VNTR-based multiplex PCR for tracing sources of Aspergillus flavus isolates. PLoS One (2012) 0.79
Invasive mold infections in solid organ transplant recipients. Scientifica (Cairo) (2014) 0.79
Triazole Susceptibilities in Thermotolerant Fungal Isolates from Outdoor Air in the Seoul Capital Area in South Korea. PLoS One (2015) 0.78
A Case Report on Aspergillus lentulus Pneumonia. Balkan Med J (2013) 0.78
Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections. Antimicrob Agents Chemother (2011) 0.77
Genetic structure of Aspergillus flavus populations in human and avian isolates. Eur J Clin Microbiol Infect Dis (2012) 0.77
Disseminated aspergillosis in a dog due to Aspergillus alabamensis. Med Mycol Case Rep (2012) 0.77
Fungal diagnostics in pneumonia. Semin Respir Crit Care Med (2011) 0.76
Misidentification of Neosartorya pseudofischeri as Aspergillus fumigatus in a lung transplant patient. J Clin Microbiol (2014) 0.76
Challenges and Strategies for Proteome Analysis of the Interaction of Human Pathogenic Fungi with Host Immune Cells. Proteomes (2015) 0.75
Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea. Ann Lab Med (2015) 0.75
Discovery of Aspergillus frankstonensis sp. nov. during environmental sampling for animal and human fungal pathogens. PLoS One (2017) 0.75
Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist (2017) 0.75
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. Appl Environ Microbiol (1995) 11.04
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell (2005) 3.44
Identification of Aspergillus species using internal transcribed spacer regions 1 and 2. J Clin Microbiol (2000) 3.41
Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia (2006) 2.59
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
Aspergillus species identification in the clinical setting. Stud Mycol (2007) 1.81
Molecular phylogenetics of multiple genes on Aspergillus section Fumigati isolated from clinical specimens in Japan. Nihon Ishinkin Gakkai Zasshi (2007) 1.56
Multiple genetically distinct groups revealed among clinical isolates identified as atypical Aspergillus fumigatus. J Clin Microbiol (2005) 1.52
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell (2008) 1.46
Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis (2008) 1.05
Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol (2008) 1.04
Polymerase chain reaction (PCR) identification of Aspergillus niger and Aspergillus tubingensis based on the calmodulin gene. Food Addit Contam (2007) 0.97
Peritonitis caused by Aspergillus sydowii in a patient undergoing continuous ambulatory peritoneal dialysis. J Infect (2005) 0.90
A case of onychomycosis due to Aspergillus sydowii diagnosed using DNA sequence analysis. Mycoses (2008) 0.87
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg (2007) 6.08
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis (2007) 3.93
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell (2005) 3.44
Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med (2012) 3.26
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect (2012) 3.24
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother (2004) 2.88
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother (2006) 2.68
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol (2006) 2.43
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis (2009) 2.37
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev (2011) 2.27
Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis (2011) 2.26
Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation (2014) 2.26
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother (2006) 2.22
LaeA, a regulator of morphogenetic fungal virulence factors. Eukaryot Cell (2005) 2.21
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis (2009) 2.19
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Comparative genome sequence analysis underscores mycoparasitism as the ancestral life style of Trichoderma. Genome Biol (2011) 2.17
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol (2008) 2.16
Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell (2006) 2.15
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med (2012) 2.12
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.11
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother (2004) 2.09
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol (2005) 2.05
Blastomycosis. Infect Dis Clin North Am (2003) 2.04
Emerging fungal diseases. Clin Infect Dis (2005) 2.03
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94